查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1706760

激酶抑制劑市場－全球產業分析、規模、佔有率、成長、趨勢及預測（2024-2034）

Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 219 Pages | 商品交期: 2-10個工作天內

價格

激酶抑制劑市場 - 報告範圍

TMR 關於全球激酶抑制劑市場的報告研究了過去和當前的成長趨勢和機會，以獲得 2024 年至 2034 年預測期內市場指標的寶貴見解。該報告提供了 2018 年至 2034 年期間全球激酶抑制劑市場的收入，以 2024 年為基準年，2034 年為預測年。該報告也提供了 2024 年至 2034 年全球激酶抑制劑市場的年複合成長率(CAGR%)。

該報告是經過廣泛研究後編寫的。初步研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了訪談。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解激酶抑制劑市場。

市場概況
2023年市場價值 580.901億美元
2034年的市場價值 899.298億美元
複合年成長率 3.9%

該報告深入探討了全球激酶抑制劑市場的競爭格局。我們已經確定了在全球激酶抑製劑市場中營運的關鍵參與者，並根據各種屬性對每個參與者進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球激酶抑制劑市場參與者的屬性。

目錄

第1章：前言

第2章：假設與研究方法

第3章：執行摘要：全球市場

第4章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020-2034年全球市場分析與預測

第5章：關鍵見解

  • 重要行業活動
  • PESTEL分析
  • 主要國家/地區監管情況
  • 波特五力分析
  • 產品/品牌分析
  • 供應鏈分析
  • 管道分析

第6章：全球市場分析與預測：依類型

  • 介紹與定義
  • 主要發現/進展
  • 2020-2034年各類型市場價值預測
    • 非受體酪胺酸
      • 布魯頓酪胺酸激酶（BTK）抑制劑
      • BCR-ABL
      • Janus激酶（JAK）抑制劑
      • 間質上皮轉化生長因子（c-MET）
      • 脾臟酪胺酸激酶（SYK）抑制劑
      • 其他
    • 酪胺酸受體
      • 血管內皮生長因子受體
      • 血小板衍生生長因子受體
      • 表皮生長因子受體
      • ALK
      • 其他
    • 多
    • 絲胺酸/蘇胺酸
    • 蛋白激酶C抑制劑
    • RHO
    • 其他
  • 不同類型的市場吸引力

第7章：全球市場分析與預測：依管理途徑

  • 介紹與定義
  • 主要發現/進展
  • 2020 年至 2034 年按給藥途徑分類的市場價值預測
    • 口服
    • 腸外及其他
  • 按給藥途徑分類的市場吸引力

第8章：全球市場分析與預測：按應用

  • 介紹與定義
  • 主要發現/進展
  • 2020 年至 2034 年各應用市場價值預測
    • 腫瘤學
      • 乳癌
      • 白血病
      • 腎癌
      • 肺癌
      • 黑色素瘤
      • 大腸直腸癌
      • 其他
    • 發炎性疾病
    • 其他
  • 按應用分類的市場吸引力

第9章：全球市場分析與預測：按最終用戶

  • 介紹與定義
  • 主要發現/進展
  • 2020 年至 2034 年終端用戶市值預測
    • 醫院藥房
    • 獨立藥局
    • 網路藥局
  • 最終用戶的市場吸引力

第10章：全球市場分析與預測：按地區

  • 主要發現
  • 各地區市場價值預測
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 各地區市場吸引力

第 11 章：北美市場分析與預測

  • 美國
  • 加拿大

第12章：歐洲市場分析與預測

  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區

第13章：亞太市場分析與預測

  • 中國
  • 印度
  • 日本
  • 澳洲和紐西蘭
  • 亞太其他地區

第14章：拉丁美洲市場分析與預測

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區

第15章：中東與非洲市場分析與預測

  • 海灣合作理事會國家
  • 南非
  • 中東和非洲其他地區

第 16 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 各公司市佔率分析（2023 年）
  • 公司簡介
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • AstraZeneca plc
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Johnson & Johnson Service, Inc.
    • Merck & Co., Inc.
    • Takeda Pharmaceuticals
    • Eisai Co., Ltd.
    • GSK Plc.
    • Eli Lilly
    • Alcon
Product Code: TMRGL818

Kinase Inhibitors Market - Scope of Report

TMR's report on the global kinase inhibitors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kinase inhibitors market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kinase inhibitors market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kinase inhibitors market.

Market Snapshot
Market Value in 2023US$ 58090.1 Mn
Market Value in 2034US$ 89929.8 Mn
CAGR3.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kinase inhibitors market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kinase inhibitors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kinase inhibitors market.

The report delves into the competitive landscape of the global kinase inhibitors market. Key players operating in the global kinase inhibitors market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kinase inhibitors market profiled in this report.

Key Questions Answered in Global kinase inhibitors Market Report:

  • What is the sales/revenue generated by kinase inhibitors across all regions during the forecast period?
  • What are the opportunities in the global kinase inhibitors market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Kinase Inhibitors Market - Research Objectives and Research Approach

The comprehensive report on the global kinase inhibitors market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kinase inhibitors market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kinase inhibitors market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Kinase Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Kinase Inhibitors Market Analysis and Forecasts, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. PESTEL Analysis
  • 5.3. Regulatory Scenario by Key Countries/Regions
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. Product/Brand Analysis
  • 5.6. Supply Chain Analysis
  • 5.7. Pipeline Analysis

6. Global Kinase Inhibitors Market Analysis and Forecasts, By Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2020-2034
    • 6.3.1. Non-receptor Tyrosine Kinase Inhibitors
      • 6.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 6.3.1.2. BCR-ABL
      • 6.3.1.3. Janus Kinase (JAK) Inhibitor
      • 6.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 6.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 6.3.1.6. Others
    • 6.3.2. Receptor Tyrosine Kinase Inhibitors
      • 6.3.2.1. VEGFR
      • 6.3.2.2. PDGFR
      • 6.3.2.3. EGFR
      • 6.3.2.4. ALK
      • 6.3.2.5. Others
    • 6.3.3. Multikinase Inhibitors
    • 6.3.4. Serine/Threonine Kinase Inhibitors
    • 6.3.5. Protein Kinase C Inhibitors
    • 6.3.6. RHO Kinase Inhibitors
    • 6.3.7. Others
  • 6.4. Market Attractiveness By Type

7. Global Kinase Inhibitors Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020-2034
    • 7.3.1. Oral
    • 7.3.2. Parenteral & Others
  • 7.4. Market Attractiveness By Route of Administration

8. Global Kinase Inhibitors Market Analysis and Forecasts, By Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Application, 2020-2034
    • 8.3.1. Oncology
      • 8.3.1.1. Breast Cancer
      • 8.3.1.2. Leukemia
      • 8.3.1.3. Renal Cancers
      • 8.3.1.4. Lung Cancer
      • 8.3.1.5. Melanoma
      • 8.3.1.6. Colorectal Cancer
      • 8.3.1.7. Others
    • 8.3.2. Inflammatory Disorders
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Application

9. Global Kinase Inhibitors Market Analysis and Forecasts, By End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By End-user, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Independent Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness By End-user

10. Global Kinase Inhibitors Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Kinase Inhibitors Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Type, 2020-2034
    • 11.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 11.2.1.2. BCR-ABL
      • 11.2.1.3. Janus Kinase (JAK) Inhibitor
      • 11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 11.2.1.6. Others
    • 11.2.2. Receptor Tyrosine Kinase Inhibitors
      • 11.2.2.1. VEGFR
      • 11.2.2.2. PDGFR
      • 11.2.2.3. EGFR
      • 11.2.2.4. ALK
      • 11.2.2.5. Others
    • 11.2.3. Multikinase Inhibitors
    • 11.2.4. Serine/Threonine Kinase Inhibitors
    • 11.2.5. Protein Kinase C Inhibitors
    • 11.2.6. RHO Kinase Inhibitors
    • 11.2.7. Others
  • 11.3. Market Value Forecast By Route of Administration, 2020-2034
    • 11.3.1. Oral
    • 11.3.2. Parenteral & Others
  • 11.4. Market Value Forecast By Application, 2020-2034
    • 11.4.1. Oncology
      • 11.4.1.1. Breast Cancer
      • 11.4.1.2. Leukemia
      • 11.4.1.3. Renal Cancers
      • 11.4.1.4. Lung Cancer
      • 11.4.1.5. Melanoma
      • 11.4.1.6. Colorectal Cancer
      • 11.4.1.7. Others
    • 11.4.2. Inflammatory Disorders
    • 11.4.3. Others
  • 11.5. Market Value Forecast By End-user, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Independent Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast By Country, 2020-2034
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Kinase Inhibitors Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Type, 2020-2034
    • 12.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 12.2.1.2. BCR-ABL
      • 12.2.1.3. Janus Kinase (JAK) Inhibitor
      • 12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 12.2.1.6. Others
    • 12.2.2. Receptor Tyrosine Kinase Inhibitors
      • 12.2.2.1. VEGFR
      • 12.2.2.2. PDGFR
      • 12.2.2.3. EGFR
      • 12.2.2.4. ALK
      • 12.2.2.5. Others
    • 12.2.3. Multikinase Inhibitors
    • 12.2.4. Serine/Threonine Kinase Inhibitors
    • 12.2.5. Protein Kinase C Inhibitors
    • 12.2.6. RHO Kinase Inhibitors
    • 12.2.7. Others
  • 12.3. Market Value Forecast By Route of Administration, 2020-2034
    • 12.3.1. Oral
    • 12.3.2. Parenteral & Others
  • 12.4. Market Value Forecast By Application, 2020-2034
    • 12.4.1. Oncology
      • 12.4.1.1. Breast Cancer
      • 12.4.1.2. Leukemia
      • 12.4.1.3. Renal Cancers
      • 12.4.1.4. Lung Cancer
      • 12.4.1.5. Melanoma
      • 12.4.1.6. Colorectal Cancer
      • 12.4.1.7. Others
    • 12.4.2. Inflammatory Disorders
    • 12.4.3. Others
  • 12.5. Market Value Forecast By End-user, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Independent Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Kinase Inhibitors Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Type, 2020-2034
    • 13.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 13.2.1.2. BCR-ABL
      • 13.2.1.3. Janus Kinase (JAK) Inhibitor
      • 13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 13.2.1.6. Others
    • 13.2.2. Receptor Tyrosine Kinase Inhibitors
      • 13.2.2.1. VEGFR
      • 13.2.2.2. PDGFR
      • 13.2.2.3. EGFR
      • 13.2.2.4. ALK
      • 13.2.2.5. Others
    • 13.2.3. Multikinase Inhibitors
    • 13.2.4. Serine/Threonine Kinase Inhibitors
    • 13.2.5. Protein Kinase C Inhibitors
    • 13.2.6. RHO Kinase Inhibitors
    • 13.2.7. Others
  • 13.3. Market Value Forecast By Route of Administration, 2020-2034
    • 13.3.1. Oral
    • 13.3.2. Parenteral & Others
  • 13.4. Market Value Forecast By Application, 2020-2034
    • 13.4.1. Oncology
      • 13.4.1.1. Breast Cancer
      • 13.4.1.2. Leukemia
      • 13.4.1.3. Renal Cancers
      • 13.4.1.4. Lung Cancer
      • 13.4.1.5. Melanoma
      • 13.4.1.6. Colorectal Cancer
      • 13.4.1.7. Others
    • 13.4.2. Inflammatory Disorders
    • 13.4.3. Others
  • 13.5. Market Value Forecast By End-user, 2020-2034
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Independent Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Kinase Inhibitors Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Type, 2020-2034
    • 14.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 14.2.1.2. BCR-ABL
      • 14.2.1.3. Janus Kinase (JAK) Inhibitor
      • 14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 14.2.1.6. Others
    • 14.2.2. Receptor Tyrosine Kinase Inhibitors
      • 14.2.2.1. VEGFR
      • 14.2.2.2. PDGFR
      • 14.2.2.3. EGFR
      • 14.2.2.4. ALK
      • 14.2.2.5. Others
    • 14.2.3. Multikinase Inhibitors
    • 14.2.4. Serine/Threonine Kinase Inhibitors
    • 14.2.5. Protein Kinase C Inhibitors
    • 14.2.6. RHO Kinase Inhibitors
    • 14.2.7. Others
  • 14.3. Market Value Forecast By Route of Administration, 2020-2034
    • 14.3.1. Oral
    • 14.3.2. Parenteral & Others
  • 14.4. Market Value Forecast By Application, 2020-2034
    • 14.4.1. Oncology
      • 14.4.1.1. Breast Cancer
      • 14.4.1.2. Leukemia
      • 14.4.1.3. Renal Cancers
      • 14.4.1.4. Lung Cancer
      • 14.4.1.5. Melanoma
      • 14.4.1.6. Colorectal Cancer
      • 14.4.1.7. Others
    • 14.4.2. Inflammatory Disorders
    • 14.4.3. Others
  • 14.5. Market Value Forecast By End-user, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Independent Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Type, 2020-2034
    • 15.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 15.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 15.2.1.2. BCR-ABL
      • 15.2.1.3. Janus Kinase (JAK) Inhibitor
      • 15.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 15.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 15.2.1.6. Others
    • 15.2.2. Receptor Tyrosine Kinase Inhibitors
      • 15.2.2.1. VEGFR
      • 15.2.2.2. PDGFR
      • 15.2.2.3. EGFR
      • 15.2.2.4. ALK
      • 15.2.2.5. Others
    • 15.2.3. Multikinase Inhibitors
    • 15.2.4. Serine/Threonine Kinase Inhibitors
    • 15.2.5. Protein Kinase C Inhibitors
    • 15.2.6. RHO Kinase Inhibitors
    • 15.2.7. Others
  • 15.3. Market Value Forecast By Route of Administration, 2020-2034
    • 15.3.1. Oral
    • 15.3.2. Parenteral & Others
  • 15.4. Market Value Forecast By Application, 2020-2034
    • 15.4.1. Oncology
      • 15.4.1.1. Breast Cancer
      • 15.4.1.2. Leukemia
      • 15.4.1.3. Renal Cancers
      • 15.4.1.4. Lung Cancer
      • 15.4.1.5. Melanoma
      • 15.4.1.6. Colorectal Cancer
      • 15.4.1.7. Others
    • 15.4.2. Inflammatory Disorders
    • 15.4.3. Others
  • 15.5. Market Value Forecast By End-user, 2020-2034
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Independent Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Type
    • 15.7.2. By Route of Administration
    • 15.7.3. By Application
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Boehringer Ingelheim International GmbH
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. AstraZeneca plc
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Pfizer, Inc.
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. F. Hoffmann-La Roche Ltd
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Bristol-Myers Squibb Company
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Bayer AG
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Johnson & Johnson Service, Inc.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Merck & Co., Inc.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Takeda Pharmaceuticals
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. Eisai Co., Ltd.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments
    • 16.3.12. GSK Plc.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Financial Overview
      • 16.3.12.3. Product Portfolio
      • 16.3.12.4. Business Strategies
      • 16.3.12.5. Recent Developments
    • 16.3.13. Eli Lilly
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Financial Overview
      • 16.3.13.3. Product Portfolio
      • 16.3.13.4. Business Strategies
      • 16.3.13.5. Recent Developments
    • 16.3.14. Alcon
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Financial Overview
      • 16.3.14.3. Product Portfolio
      • 16.3.14.4. Business Strategies
      • 16.3.14.5. Recent Developments

List of Tables

  • Table 01: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 02: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 03: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 04: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 05: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 06: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 07: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 08: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Region, 2020-2034
  • Table 09: North America - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 10: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 11: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 12: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 13: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 14: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 15: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 17: Europe - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 18: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 19: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 20: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 21: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 22: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 25: Asia Pacific - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 26: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 27: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 28: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 29: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 33: Latin America - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 34: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 35: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 36: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 41: Middle East & Africa - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 42: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 43: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034

List of Figures

  • Figure 01: Global Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 02: Global Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 03: Global Kinase Inhibitors Market Revenue (US$ Mn), by Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Figure 04: Global Kinase Inhibitors Market Revenue (US$ Mn), by Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Figure 05: Global Kinase Inhibitors Market Revenue (US$ Mn), by Multikinase Inhibitors, 2020-2034
  • Figure 06: Global Kinase Inhibitors Market Revenue (US$ Mn), by Serine/Threonine Kinase Inhibitors, 2020-2034
  • Figure 07: Global Kinase Inhibitors Market Revenue (US$ Mn), by Protein Kinase C Inhibitors, 2020-2034
  • Figure 08: Global Kinase Inhibitors Market Revenue (US$ Mn), by RHO Kinase Inhibitors, 2020-2034
  • Figure 09: Global Kinase Inhibitors Market Revenue (US$ Mn), by Others, 2020-2034
  • Figure 10: Global Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 11: Global Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 12: Global Kinase Inhibitors Market Revenue (US$ Mn), by Oral, 2020-2034
  • Figure 13: Global Kinase Inhibitors Market Revenue (US$ Mn), by Parenteral, 2020-2034
  • Figure 14: Global Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 15: Global Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 16: Global Kinase Inhibitors Market Revenue (US$ Mn), by Breast Cancer, 2020-2034
  • Figure 17: Global Kinase Inhibitors Market Revenue (US$ Mn), by Chronic myeloid leukemia (CML), 2020-2034
  • Figure 18: Global Kinase Inhibitors Market Revenue (US$ Mn), by Renal Cancers, 2020-2034
  • Figure 19: Global Kinase Inhibitors Market Revenue (US$ Mn), by Lung Cancer, 2020-2034
  • Figure 20: Global Kinase Inhibitors Market Revenue (US$ Mn), by Metastatic melanoma, 2020-2034
  • Figure 21: Global Kinase Inhibitors Market Revenue (US$ Mn), by Soft tissue sarcoma, 2020-2034
  • Figure 22: Global Kinase Inhibitors Market Revenue (US$ Mn), by Others, 2020-2034
  • Figure 23: Global Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 24: Global Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 25: Global Kinase Inhibitors Market Revenue (US$ Mn), by Hospital Pharmacies, 2020-2034
  • Figure 26: Global Kinase Inhibitors Market Revenue (US$ Mn), by Independent Pharmacies, 2020-2034
  • Figure 27: Global Kinase Inhibitors Market Revenue (US$ Mn), by Online Pharmacies, 2020-2034
  • Figure 28: Global Kinase Inhibitors Market Value Share Analysis, By Region, 2023 and 2034
  • Figure 29: Global Kinase Inhibitors Market Attractiveness Analysis, By Region, 2024-2034
  • Figure 30: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 31: North America Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 32: North America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 33: North America Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 34: North America Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 35: North America Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 36: North America Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 37: North America Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 38: North America Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 39: North America Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 40: North America Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 41: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 42: Europe Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 43: Europe Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 44: Europe Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 45: Europe Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 46: Europe Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 47: Europe Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 48: Europe Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 49: Europe Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 50: Europe Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 51: Europe Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 52: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 53: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 54: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 55: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 56: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 57: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 58: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 59: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 60: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 61: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 62: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 63: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 64: Latin America Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 65: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 66: Latin America Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 67: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 68: Latin America Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 69: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 70: Latin America Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 71: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 72: Latin America Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 73: Latin America Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 74: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 75: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 76: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 77: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 78: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 79: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 80: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 81: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 82: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 83: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 84: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034